Longboard Pharmaceuticals IncNASDAQ:LBPH
- LAST PRICE18.8000
- TODAY'S CHANGE (%)-0.1400 (-0.7392%)
- Bid / Lots18.0100/ 4
- Ask / Lots21.4900/ 1
- Open / Previous Close19.3500 / 18.9400
- Day Range
- 52 Week Range
- Volume167,001
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LBPH |
|---|---|---|
| 09:32 ET | 817 | 19.35 |
| 09:36 ET | 1150 | 19.18 |
| 09:38 ET | 300 | 18.97 |
| 09:39 ET | 100 | 19.13 |
| 09:45 ET | 1600 | 19.19 |
| 09:48 ET | 1132 | 19.12 |
| 09:50 ET | 848 | 19.11 |
| 09:52 ET | 100 | 19.08 |
| 09:59 ET | 100 | 19.01 |
| 10:03 ET | 3088 | 18.69 |
| 10:10 ET | 167 | 18.5678 |
| 10:14 ET | 100 | 18.76 |
| 10:15 ET | 1626 | 18.69 |
| 10:21 ET | 300 | 18.41 |
| 10:28 ET | 600 | 18.605 |
| 10:30 ET | 200 | 18.695 |
| 10:33 ET | 100 | 18.63 |
| 10:35 ET | 124 | 18.665 |
| 10:39 ET | 100 | 18.69 |
| 10:42 ET | 100 | 18.675 |
| 10:46 ET | 200 | 18.69 |
| 10:48 ET | 1100 | 18.69 |
| 10:53 ET | 500 | 18.68 |
| 10:57 ET | 300 | 18.72 |
| 11:00 ET | 218 | 18.725 |
| 11:02 ET | 100 | 18.715 |
| 11:04 ET | 900 | 18.715 |
| 11:06 ET | 500 | 18.715 |
| 11:11 ET | 500 | 18.715 |
| 11:13 ET | 1773 | 18.825 |
| 11:18 ET | 409 | 18.845 |
| 11:20 ET | 1437 | 18.78 |
| 11:27 ET | 100 | 18.795 |
| 11:31 ET | 100 | 18.795 |
| 11:33 ET | 400 | 18.75 |
| 11:36 ET | 3095 | 18.645 |
| 11:38 ET | 200 | 18.6 |
| 11:42 ET | 100 | 18.6 |
| 11:49 ET | 100 | 18.654 |
| 11:54 ET | 100 | 18.64 |
| 12:00 ET | 400 | 18.62 |
| 12:02 ET | 700 | 18.63 |
| 12:03 ET | 239 | 18.655 |
| 12:05 ET | 14286 | 18.715 |
| 12:07 ET | 564 | 18.655 |
| 12:09 ET | 200 | 18.64 |
| 12:12 ET | 200 | 18.64 |
| 12:14 ET | 100 | 18.64 |
| 12:16 ET | 200 | 18.64 |
| 12:18 ET | 700 | 18.66 |
| 12:20 ET | 200 | 18.67 |
| 12:21 ET | 911 | 18.725 |
| 12:23 ET | 300 | 18.69 |
| 12:25 ET | 483 | 18.725 |
| 12:27 ET | 657 | 18.69 |
| 12:32 ET | 1119 | 18.69 |
| 12:36 ET | 1300 | 18.76 |
| 12:38 ET | 900 | 18.71 |
| 12:43 ET | 600 | 18.73 |
| 12:45 ET | 100 | 18.73 |
| 12:48 ET | 200 | 18.765 |
| 12:50 ET | 1800 | 18.67 |
| 12:54 ET | 378 | 18.685 |
| 12:56 ET | 800 | 18.65 |
| 12:57 ET | 300 | 18.69 |
| 12:59 ET | 177 | 18.69 |
| 01:01 ET | 100 | 18.65 |
| 01:03 ET | 100 | 18.73 |
| 01:12 ET | 503 | 18.77 |
| 01:17 ET | 400 | 18.87 |
| 01:19 ET | 200 | 18.84 |
| 01:21 ET | 100 | 18.885 |
| 01:30 ET | 1600 | 18.76 |
| 01:32 ET | 100 | 18.795 |
| 01:33 ET | 100 | 18.87 |
| 01:37 ET | 100 | 18.89 |
| 01:39 ET | 200 | 18.89 |
| 01:42 ET | 100 | 18.9 |
| 01:46 ET | 200 | 18.9 |
| 01:48 ET | 400 | 18.86 |
| 01:50 ET | 900 | 18.78 |
| 01:51 ET | 100 | 18.73 |
| 01:53 ET | 100 | 18.8 |
| 02:04 ET | 200 | 18.87 |
| 02:06 ET | 500 | 18.79 |
| 02:09 ET | 1100 | 18.76 |
| 02:15 ET | 100 | 18.77 |
| 02:18 ET | 200 | 18.76 |
| 02:20 ET | 300 | 18.815 |
| 02:22 ET | 200 | 18.85 |
| 02:24 ET | 200 | 18.885 |
| 02:26 ET | 300 | 18.84 |
| 02:27 ET | 800 | 18.76 |
| 02:29 ET | 100 | 18.78 |
| 02:31 ET | 400 | 18.74 |
| 02:40 ET | 100 | 18.8 |
| 02:42 ET | 300 | 18.72 |
| 02:44 ET | 800 | 18.7599 |
| 02:45 ET | 100 | 18.68 |
| 02:47 ET | 100 | 18.72 |
| 02:51 ET | 100 | 18.721 |
| 02:58 ET | 200 | 18.7 |
| 03:00 ET | 100 | 18.76 |
| 03:02 ET | 549 | 18.66 |
| 03:03 ET | 100 | 18.65 |
| 03:05 ET | 200 | 18.7 |
| 03:07 ET | 258 | 18.7 |
| 03:16 ET | 300 | 18.77 |
| 03:18 ET | 1100 | 18.75 |
| 03:20 ET | 200 | 18.79 |
| 03:21 ET | 100 | 18.81 |
| 03:25 ET | 300 | 18.82 |
| 03:32 ET | 570 | 18.87 |
| 03:34 ET | 1000 | 18.86 |
| 03:36 ET | 300 | 18.85 |
| 03:38 ET | 100 | 18.855 |
| 03:39 ET | 103 | 18.88 |
| 03:41 ET | 200 | 18.87 |
| 03:43 ET | 4876 | 18.74 |
| 03:45 ET | 914 | 18.8 |
| 03:48 ET | 900 | 18.79 |
| 03:52 ET | 200 | 18.85 |
| 03:54 ET | 1906 | 18.83 |
| 03:56 ET | 100 | 18.855 |
| 03:57 ET | 2506 | 18.79 |
| 03:59 ET | 4535 | 18.8 |
May 7, 2024
DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 10:48AM ET on Tuesday May 07, 2024 by Dow Jones
10:48AM ET on Tuesday May 07, 2024 by Dow Jones
May 6, 2024
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4), from 4:01PM ET on Monday May 06, 2024 by Dow Jones
4:01PM ET on Monday May 06, 2024 by Dow Jones
May 3, 2024
DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Cantor Fitzgerald, from 11:08AM ET on Friday May 03, 2024 by Dow Jones
11:08AM ET on Friday May 03, 2024 by Dow JonesDJ Longboard Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:50AM ET on Friday May 03, 2024 by Dow Jones
9:50AM ET on Friday May 03, 2024 by Dow Jones
May 2, 2024
Press Release: Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates, from 4:02PM ET on Thursday May 02, 2024 by Dow Jones
4:02PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Longboard Pharmaceuticals Inc | 736.4M | -8.3x | --- |
Cogent Biosciences Inc | 716.1M | -3.3x | --- |
Praxis Precision Medicines Inc | 730.7M | -2.8x | --- |
Nuvation Bio Inc | 761.3M | -9.8x | --- |
ALX Oncology Holdings Inc | 765.4M | -3.5x | --- |
Viridian Therapeutics Inc | 776.1M | -2.7x | --- |
Company Information
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Contact Information
- Headquarters
- 4275 Executive Square, Suite 950LA JOLLA, CA, United States 92037
- Phone
- 619-592-9775
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Paul Sekhri
- President, Chief Executive Officer, Director
- Kevin Lind
- Chief Financial Officer, Executive Vice President
- Brandi Roberts
- Executive Vice President, Chief Medical Officer
- Randall Kaye
- Independent Director
- Vincent Aurentz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $736.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $1.67 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
